TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age less than 70 years old~2. Normothermia (36.5 degrees centigrade)~3. Normal sinus rhythm~4. Hemodynamically stable (systolic blood pressure \[SBP\] \> 110 mmHg)~5. Ejection fraction (EF) \> 40%/absence of congestive heart failure (CHF)~6. Cardiac index \> 2.5 L/min/m2~7. Minimal inotropic support (\< 3 mcg/kg/min dobutamine)~8. Adequate coagulation profile~9. Adequate urine output (\> 100 ml/hr)~10. Primary service and critical care physician agreement~Exclusion Criteria:~1. Prior use of clonidine or alpha-antagonists~2. Prior history of intravenous drug abuse (IVDA) or alcohol abuse (ETOH)~3. Evidence of heart block~4. Difficulty with oxygenation/ventilation~5. Renal or hepatic insufficiency~6. Pregnant (positive urine or serum pregnancy test upon admission)~7. Patient received dexmedetomidine \> 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Standard Hospital Ventilation Weaning Protocol (Type: NO_INTERVENTION): Control. Hospital weaning protocol
- Dexmedetomidine for Extubation (Type: EXPERIMENTAL): Dexmedomidine infusion to facilitate extubation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lifestyle and Non-motor Symptom Management in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~A) Patients~* A diagnosis of idiopathic Parkinson's Disease~* Age of 18 years or above~* Current or previous experience of persistent fatigue~* Able to communicate clearly in English over the telephone/online for over an hour~* Have access to a working computer and internet connection (required for stage 2 only).~B) Supportive person (partner/family member/caregiver)~* Age of 18 years or above~* A supportive person of an individual with Parkinson's Disease whom has already consented to take part in the research. Supportive individuals cannot take part without an associated individual with Parkinson's Disease having already consented.~* Has regular contact with and is involved in the care and/or support of an individual diagnosed with Idiopathic Parkinson's Disease.~* Able to communicate clearly in English over the telephone/online for over an hour~* Have access to a working computer and internet connection (required for stage 2 only).~C) Healthcare Professionals~* Healthcare Professional with at least 2 years experience of Parkinson's disease treatment/management/clinical care and/or an academic currently working in the area of Parkinson's Disease treatment.~* Have access to a working computer and internet connection (required for stage 2 only).~Exclusion criteria~A) Patients~* Reduced cognition that would preclude active involvement and capacity to consent to participate~* Unable to communicate clearly in English over the telephone/online for over an hour.~B) Partners/Caregivers~* Reduced cognition that would preclude active involvement and capacity to consent to participate~* Unable to communicate clearly in English over the telephone/online for over an hour.~C) Health Care Professional~* Less than 2 years' experience in the treatment/management/clinical care of individuals with Parkinson's disease as determined by self-report~* They have worked in this field but have stopped for two years or more.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Individuals with Parkinson's Disease (Type: None): None
- Supportive individuals (Type: None): For example carers, family members or any other individual providing regular support or care to the person with Parkinson's.
- Healthcare Professionals (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and older~* ASA I-III~* Indication for an elective tumor surgery within the GI tract (stomach, small intestine, large intestine)~* Written informed consent~Exclusion Criteria:~* Emergency surgery~* Peritonitis~* Patients undergoing an operation due to a tumour within the pancreas, rectum, esophagus~* Pregnant women and breast-feeding women~* Chemotherapy~* Current immunosuppressive therapy~* Radiotherapy on the treated region within the last 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monosyn (Type: None): Construction of a gastrointestinal anastomoses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a Dynamic Evaluation Tool in Respiratory Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volonteers Man or woman of more than 18 years Realization of a preliminary medical examination Patient having signed an informed and written consent Major healthy subjects, presenting no chronic pathology or not chronic patients~Chronic patients Man or woman of more than 18 years Affected by neuromuscular pathology Realization of a preliminary medical examination Patient in the stable state at the time of the study for at least 1 month Ventilated in a not invasive or invasive way in diurnal and night-period. Respiratory autonomy \> 1:00 am Patient having signed an informed and written consent~Acute Patients Man or woman of more than 18 years Affected by syndrome of Guillain blocked in aigue phase having required the invasive ventilation or affected by myasthenia generalized with myasthénique crisis having required the invasive ventilation.~Realization of a preliminary medical examination Patient in phase of neurological recovery Vital Capacity \> 15 ml / kg Respiratory Autonomy \> 1:00 am Patient having signed a lit(enlightened) and written consent~Exclusion Criteria:~Healthy volonteers subject refusing to participate in the study subject under guardianship or guardianship Pregnant or breast-feeding Woman~Chronic patients Patient refusing to participate in the study Patient under guardianship or guardianship Pregnant or breast-feeding Woman Patients ventilated only at night Clinically significant bronchial Dimensions(Congestion) Required by oxygen therapy~Acute patients Patient refusing to participate in the study Patient or subject under guardianship or guardianship Pregnant or breast-feeding Woman Clinically significant bronchial Dimensions(Congestion) Required by oxygen therapy FIO2 \> 40 % PEP \> 5 cms H2O State of shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- healthy volunteers (Type: EXPERIMENTAL): Free breath monitoring. Correlation between two device for recording parameters of ventilation.
- Chronic patient (Type: EXPERIMENTAL): Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
- ACUTE PATIENT (Type: EXPERIMENTAL): Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 65 years~2. Body mass index (BMI) \>=25;~3. Currently taking a regimen of medications for bipolar disorder likely to cause, sedation, weight gain or undesirable metabolic effects;~4. Able to give basic informed consent~5. Meets DSM-IV criteria for lifetime bipolar I or II disorder and are presently in sustained remission (CGI BP\<3 in the previous 8-week period measured through a complete psychiatric history at screening and patient report.)~6. Epworth Scale Score \> 7~7. Women of childbearing potential must agree to use a doctor-approved birth control throughout participation in the study~Exclusion Criteria:~1. Unwilling or unable to comply with study requirements (i.e., complete forms, attend scheduled evaluations)~2. Not competent to provide informed consent in the opinion of the investigator~3. Ultra-rapid cycling (\>4 episodes per month) bipolar I disorder~4. Unstable and severe medical illness that requires immediate and intensive medical attention, When appropriate, the patients can be reconsidered for inclusion in the study if/when their medical condition becomes compatible with participation in a protocol-driven research study~5. Women who are planning to become pregnant, currently pregnant, or breast-feeding;~6. Current substance dependence; however, if a subject only has substance abuse/use, after the first positive drug screen, another drug screen will be repeated. If that drug screen is positive, the subject will be excluded. If the second drug screen is negative, the subject will be considered for the study;~7. Subjects who have previously failed an adequate trial of aripiprazole.~8. Subjects with a suicide attempt in the past 2 years;~9. Subjects with a history of inpatient admission in the past 1 year;~10. Subjects with a history of homicidal ideation;~11. Any subject for whom the PI deems that the potential risks in participating in the study outweigh the potential benefits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Aripiprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to be on acceptable method of birth control~* Have a Pap smear result of LSIL or ASCUS~* Is high risk HPV positive~Exclusion Criteria:~* No evidence of high-grade disease or glandular abnormalities,~* Complete visualization of all lesion margins and the transformation zone,~* No uncontrolled significant medical illness or sexually transmitted infections,~* Taking any restricted medications such as interferon, immunomodulators, cytotoxic drugs, investigational drugs, steroids.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- 6 (Type: EXPERIMENTAL): None
- 7 (Type: EXPERIMENTAL): None
- 8 (Type: EXPERIMENTAL): None
- 9 (Type: EXPERIMENTAL): None
- 10 (Type: EXPERIMENTAL): None
- 11 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Midazolam Levels in Follicular Fluid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infertility (prim. / sec.)~* Age \>18 - ≤ 38 years.~* BMI 19-30~* Stimulation in GnRH-antagonist protocol, using rFSH~* Expected normal ovarian response (6)~* At least 4 follicles with the size ≥ than 17 mm on the day of OPU~* Patients undergoing PGS~* Able to understand the aim of the study and to provide consent~Exclusion Criteria:~* History of endometriosis, classified according to the American Fertility Society (AFS) as stage 3 or more.~* Severe male factor

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- Control group using Propofol (Type: NO_INTERVENTION): Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
- Study group Midazolam group (Type: EXPERIMENTAL): Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autonomic Cardiovascular Control for Elderly Surgery Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital~Exclusion Criteria:~* Absence of a valid informed consent or assent, or consent from a legal proxy~* Patients with atrial fibrillation or a pacemaker rhythm~* Polyneuropathy~* Current treatment with beta-blockers, calcium-blockers or cholinesterase inhibitors~* Competing research project

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abdominal surgery (Type: None): Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalised for chest pain and potential acute coronary syndrome.~* Onset of the most recent cardiac ischemic symptoms must occur within 7 days before randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at rest and at least 2 of the following: ST segment changes on electrocardiogram (ECG) indicative of ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk factors such as: 60 yrs of age or older, previous myocardial infarction or coronary bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral arterial disease, chronic renal disfunction.~* Females must be either surgically sterile or post-menopausal.~* Activated Clotting Time (ACT) \</= 300 at the time of study treatment~Exclusion Criteria:~* Participation in another clinical study with an investigational product during the last 30 days.~* Current acute complication of percutaneous coronary intervention or coronary bypass surgery.~* Any contraindication to ticagrelor, clopidogrel or bivalirudin.~* ST elevation myocardial infraction within 24 hours of study entry.~* Any indications for oral anticoagulation or aspirin dose other than 75 to 100 milligrams (mg) daily.~* Planned use of omeprazole or esomeprazole.~* Patients with known bleeding or coagulation disorders; patients requiring dialysis; patients who have an inability to swallow medication.~* Patients with known bleeding diathesis or coagulation disorder; history of intracranial bleed.~* Use of Intravenous (IV) heparin less than 2 hours before procedure.~* Sustained uncontrolled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): 90 mg oral tablet
- Clopidogrel (Type: ACTIVE_COMPARATOR): 300 mg oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parkinson's disease diagnosis~* Currently taking a levodopa containing medication for Parkinson's disease~* Mild to Severe dyskinesia~* Currently taking between 200-500 mg of amantadine daily for treatment of levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia.~* Stable medication regimen for at least 4 weeks prior to study.~Exclusion Criteria:~* Currently receiving any other treatment for levodopa-induced dyskinesia, including but not exclusive to deep brain stimulation.~* Not able to follow verbal commands~* Not able to stand unsupported for at least 60 seconds~* Not able to answer a patient questionnaire about their symptoms of Parkinson's disease and dyskinesia.~* Have proprioceptive deficits.~* Have a history of hepatic impairment~* Currently have severe renal impairment~* Currently have any other medical or psychiatric diagnosis that would preclude their ability to safely participate in the study.~* Significant cognitive impairment~* Pregnancy~* Breast-Feeding~* Unable to swallow study drug (capsule)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Buspirone (Type: EXPERIMENTAL): Two week titration up to 10 mg tablet/3 times a day for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Two week titration up to 3 tablets/3 times a day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be \>/= 18 years old and able to provide consent~* Must have diagnosis of CLL as defined by NCI criteria~* Must be previously untreated for CLL~* Must require chemotherapy~* serum creatinine \<1.8 mg/dl~* Bilirubin must be \</= 2 mg/d, unless secondary to tumor~* Must have adequate liver function (as defined as \<2x ULN, unless related to CLL)~* Performance status 0-2~* Women of child bearing age must be willing to use accepted/effective method of birth control.~Exclusion Criteria:~* Not have received prior treatment with cytotoxic chemotherapy or immunotherapy.~* Not have autoimmune hemolytic anemia or autoimmune thrombocytopenia~* Not have history of corticosteroid treatment for CLL~* Not have CNS disease~* Not have clinically significant infections~* Patients with a second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix are not eligible.~* Not have positive serology for Hepatitis B or Hepatitis C~* Not have be known to be HIV positive~* Not have New York Classification III or IV hear disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ofatumumab + bendamustine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Establishment of Normal Muscle Strength for French Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Age 18-90 years~Exclusion Criteria:~* Patients \< 20 years and \> 90 years,~* Athletes involved in international sport competition~* Rheumatic or neuromuscular disease~* Other decompensated pathological conditions~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- muscle strength ,muscle mass (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Endoscopic Barrett's Esophagus Diagnosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of (h/o) GERD~* Upper GI symptoms such as acid taste in mouth, dysphagia, dyspepsia~* Screening or surveillance exam for BE~Exclusion Criteria:~* Unable to consent~* History of esophageal varices

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues